Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Prices
  • 5 mg - 103 EUR
  • 25 mg - 412 EUR
  • 100 mg - 1236 EUR

Rapamycin

Rapamycin is an immunosuppressant used to prevent rejection in organ transplantation. Due to its antiproliferative properties, it is also being tested as an anticancer drug. Rapamycin is a bacterial product that inhibits the mTOR kinase by associating with its intracellular receptor FKBP12; the FKBP12-rapamycin complex binds directly to mTOR.

catalogue number: R060
synonyms: Sirolimus, Rapamune
CAS: 53123-88-9
MW: 914.18 g/mol

References
Curr Med Chem. 2011;18(20):2995-3014. PMID: 21651476
www.rapamune.com

Prices
  • 5 mg - 148 EUR
  • 25 mg - 592 EUR
  • 100 mg - 1776 EUR

Regorafenib

Regorafenib is an orally available multi-kinase inhibitor that targets several receptor tyrosine kinases, with IC50 values of 17, 40 and 69 nM for c-KIT, VEGFR2, B-Raf. It is currently being studied in the treatment of multiple tumor types.

catalogue number: R104
synonyms: BAY73-4506
CAS: 755037-03-7
MW: 482.82 g/mol

References
Int J Cancer. 2011 Jul 1;129(1):245-55. PMID: 21170960

Prices
  • 100 mg - 65 EUR
  • 250 mg - 125 EUR
  • 500 mg - 260 EUR

Resveratrol

Resveratrol is a phytoalexin produced by several plants attacked by pathogens. In human cells it displays antitumor, antioxidant, antiplatelet, anti-inflammatory and antifungal effects. Resveratrol inhibits cytochrome P450 1A1, cyclooxygenase-1 (COX-1), interacts with estrogen receptors ER-alpha and ER-beta, activates sirtuin 1 (SIRT1).

catalogue number: R135
synonyms: (E)-Resveratrol
CAS: 501-36-0
MW: 228.25 g/mol

References
Epigenetics. 2011 Jul;6(7):870-4. PMID: 21613817
Anticancer Agents Med Chem. 2011 Jun;11(5):479-90. PMID: 21524243

Prices
  • 5 mg - 41 EUR
  • 25 mg - 164 EUR
  • 100 mg - 492 EUR

(R/S)-roscovitine

Roscovitine is a highly efficient and selective inhibitor of certain cyclin-dependent kinases, including CDK2, CDK5, CDK7 and CDK9. It reversibly halts the cell cycle and DNA synthesis in several model systems and inhibits proliferation in various mammalian cell lines with an average IC50 of 16 microM.

catalogue number: R067
synonyms:
CAS: 186692-44-4
MW: 354.45 g/mol

References
J Med Chem. 1997 Feb 14;40(4):408-12. PMID: 9046330
Acc Chem Res. 2003 Jun;36(6):417-25. PMID: 15648953
Curr Opin Investig Drugs. 2004 Dec;5(12):1311-8. PMID: 15648953

Prices
  • 5 mg - 41 EUR
  • 25 mg - 164 EUR
  • 100 mg - 492 EUR

(R)-roscovitine

Roscovitine is a highly efficient and selective inhibitor of certain cyclin-dependent kinases, including CDK2, CDK5, CDK7 and CDK9. It reversibly halts the cell cycle and DNA synthesis in several model systems and inhibits proliferation in various mammalian cell lines with an average IC50 of 16 microM.

catalogue number: R070
synonyms: seliciclib, CYC202
CAS: 186692-46-6
MW: 354.45 g/mol

References
J Med Chem. 1997 Feb 14;40(4):408-12. PMID: 9046330
Acc Chem Res. 2003 Jun;36(6):417-25. PMID: 15648953
Curr Opin Investig Drugs. 2004 Dec;5(12):1311-8. PMID: 15648953

Prices
  • 5 mg - 41 EUR
  • 25 mg - 164 EUR
  • 100 mg - 492 EUR

(S)-roscovitine

Roscovitine is a highly efficient and selective inhibitor of certain cyclin-dependent kinases, including CDK2, CDK5, CDK7 and CDK9. In addition to its anticancer activities (and in contrast to the R isomer), S-roscovitine is being studied as a potential neuroprotectant for stroke because it can cross the blood brain barrier. In the brain, its inhibition of CDK5 blocks hypoxia-induced apoptosis in neurons.

catalogue number: R074
synonyms:
CAS: 186692-45-5
MW: 354.45 g/mol

References
J Med Chem. 1997 Feb 14;40(4):408-12. PMID: 9046330
Acc Chem Res. 2003 Jun;36(6):417-25. PMID: 15648953
Nat Rev Neurol. 2010 Oct;6(10):527. PMID: 20949660

Prices
  • 5 mg - 647 EUR
  • 25 mg - 2558 EUR
  • 100 mg - 7764 EUR

R547

R547 is a CDK inhibitor (Ki = 1, 3, and 1 nM for CDK1, CDK2, and CDK4, respectively) with excellent in vitro cellular potency that inhibits the growth of various human tumor cell lines. Its growth-inhibitory activity is characterized by cell cycle blockage in the G(1) and G(2) phases, reduced phosphorylation of the cellular retinoblastoma protein, and induction of apoptosis.

catalogue number: R068
synonyms:
CAS: 741713-40-6
MW: 441.45 g/mol

References
J Med Chem. 2006 Nov 2;49(22):6549-60. PMID: 17121911
Mol Cancer Ther. 2006 Nov;5(11):2644-58. PMID: 17064073

Prices
  • 5 mg - on request
  • 25 mg - on request
  • 100 mg - on request

RGB-286638

RGB-286638 is a cyclin-dependent kinase inhibitor with IC50 values of 1, 2, 3 and 44 nM for CDK9, CDK1, CDK2, and CDK4, respectively. It has been shown to inhibit cell cycle progression in cancer cells by targeting CDKs, and was also found to induce apoptosis. In a range of pre-clinical models of solid and hematological tumors, RGB-286638 treatment resulted in tumor regression and increased survival.

catalogue number: R069
synonyms:
CAS: 784210-88-4
MW: 545.65 g/mol

References
J Pharm Biomed Anal. 2009 Dec 5;50(5):977-82. PMID: 19628352

Prices
  • 5 mg - 185 EUR
  • 25 mg - 745 EUR
  • 100 mg - 2220 EUR

Ruxolitinib

Ruxolitinib is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM). It inhibits the proliferation of JAK2V617F-positive cells. In a mouse model of JAK2V617F-positive MPN, it markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells. This significantly increased survival without myelo- or immunosuppression.

catalogue number: R106
synonyms: INCB018424
CAS: 941678-49-5
MW: 306.37 g/mol

References
Org Lett. 2009 May 7;11(9):1999-2002. PMID: 19385672
Blood. 2010 Apr 15;115(15):3109-17. PMID: 20130243
J Immunol. 2010 May 1;184(9):5298-307. PMID: 20363976